[Sinopharm Modern: Its holding subsidiary withdraws the registration application for cyclophosphamide injection] On November 5, Sinopharm Modern (600420.SH) announced that the company's holding subsidiary Sinopharm Yixin received the "Notice of Termination of Drug Registration Application" issued by the State Food and Drug Administration and agreed to withdraw the registration application for cyclophosphamide injection. This drug is mainly suitable for malignant lymphoma, multiple myeloma, leukemia, etc. As of now, no domestic manufacturer has been approved for marketing. Sinopharm Yixin has invested a total of approximately 12.747 million yuan in R&D. This withdrawal will not have a significant impact on the company's current operating results.